These online education programs provide information in a variety of selected areas of laboratory medicine. Make sure to share these programs with colleagues at your institution… they will be glad you did!
Sign up now for the November 19 presentation. Registration is free.
The recent FDA approval of a new biomarker for acute kidney injury (AKI) gives clinicians one more tool to help identify patients at risk of developing AKI, a condition that is now recognized as a major risk factor for chronic kidney disease progression. Join AACC for this FREE 60-minute webinar and learn how clinicians are incorporating recently approved biomarkers of AKI into patient assessment, with the goal of improving patient outcomes through earlier therapeutic intervention.
Sign up now for the November 13 presentation. Registration is free.
As questions continue to arise about how best to test patients suspected of having contracted the Ebola virus, laboratorians are looking for information that will guide their decision-making. There are many instructional posters, papers and guidelines now available (check out AACC’s Ebola resource page
), but there’s no substitute for experience.
Join AACC for this exclusive 60-minute free webinar and hear what laboratorians who have actually tested Ebola virus patients learned from this process. Register for this webinar and hear how Emory University and NIH laboratory leaders prepared to test their Ebola patients, what they learned while testing the patients in their care, and what they would do differently in the future.
New clinical trial data comparing cervical cancer screening methods led to the recent FDA approval of an HPV DNA test as a primary screen in women 25 and older—just the latest development in this dynamic area of laboratory testing. Join AACC for this 60-minute FREE webinar, supported by an educational grant from Roche Diagnostics, and hear Mark H. Stoler, MD, discuss the new data and what it means for the future of cervical cancer screening, what constitutes a "clinically validated" HPV test, and what the advantages and limitations of using today's FDA-cleared HPV testing technologies are in the context of these new developments.
The LIS is getting more complex. Now that automated chemistry, immunoassay and molecular diagnostics systems have moved into the mainstream, clinical labs now must decide how best to incorporate mass spec tools into their institutions' existing test processes and information systems. To date, integration with LIS/HIS infrastructure has been a challenge. Automated data review of lab results has been a cornerstone in efforts to improve patient safety, patient health outcomes, and lab efficiency. Find out now what your current options are for mass spec/LIS connectivity, as learn best practice considerations for automating MS data review.
JUNE 2014The Risks and Rewards of Social Media for Laboratory Professionals
(A member only benefit.)
Confused, stressed, or afraid of taking the plunge into social media? You're not alone. Many scientists, including laboratory professionals, feel uneasy about sharing on social media—or don't see a reason why in the first place.
In this two-part webcast, Tiffany Roberts PhD, explains why laboratory professionals should explore social media as part of their professional life, as well as how novices can get started if they're not sure where to begin.
Amyloidosis is a disorder in which abnormal proteins build up in tissues and organs. Clumps of the abnormal proteins, called amyloid deposits, can build up in certain organs, reducing their ability to work correctly. Definitive diagnosis is made by a biopsy examination for evidence of characteristic amyloid deposits, but treatment strategies are often determined by the additional information gained by protein subtyping. View this presentation and find out why LC-MS protein identification may be the answer to the significant challenges posed by antibody-based investigations.
Testing for low-density lipoprotein cholesterol can help determine an individual's risk of heart disease and help guide decisions about what treatment may be best if the person is at borderline or high risk. The results are considered along with other known risk factors of heart disease to develop a plan of treatment and follow up. Treatment options may involve lifestyle changes, such as diet and exercise, or lipid-lowering medications such as statins.
Although mass spec has been used in the clinical lab for decades, it has mainly focused on specialized testing such as newborn screening and metabolic disorders. As a result, clinical laboratorians and pathologists have had limited access to this essential method. This webcast highlights the latest developments in LC/MS technology designed to make mass spec testing accessible for clinical laboratories of all sizes and volumes.
Learn more about mentoring or developing a mentoring program in clinical laboratory science with these practical tips and resources. CLICK HERE
if you are a Point of Care professional interested in learning about mentoring programs.
Professional Success Series
Practical suggestions and tools for conducting successful job interviews, networking, submitting a manuscript for publication, and preparing an abstract for a scientific conference.